Radioimmunotherapy of human tumours (original) (raw)
Malaise, E. P., Fertil, B., Chavaudra, N. & Guichard, M. Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data. Int. J. Radiat. Oncol. Biol. Phys.12, 617–624 (1986). ArticleCASPubMed Google Scholar
Scott, A. M., Wolchok, J. D. & Old, L. J. Antibody therapy of cancer. Nature Reviews Cancer12, 278–287 (2012). Valuable review of the general concepts of antigen targets on human tumours and the non-radioactive use of antibodies as therapeutics. ArticleCASPubMed Google Scholar
Kaminski, M. S. et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med.352, 441–449 (2005). Benefits of up-front treatment by RIT in lymphoma. ArticleCASPubMed Google Scholar
Press, O. W. et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med.329, 1219–1224 (1993). First demonstration of the ability to achieve long-term remission with radioantibodies using RIT in advanced lymphoma. ArticleCASPubMed Google Scholar
Witzig, T. E. et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol.20, 3262–3269 (2002). ArticleCASPubMed Google Scholar
DeNardo, G. L. et al. Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J. Clin. Oncol.16, 3246–3256 (1998). ArticleCASPubMed Google Scholar
Sharkey, R. M. et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J. Nucl. Med.50, 444–453 (2009). ArticleCASPubMed Google Scholar
Morschhauser, F. et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, Phase I/II study in non-Hodgkin's lymphoma. J. Clin. Oncol.28, 3709–3716 (2010). ArticleCASPubMed Google Scholar
Rosenblat, T. L. et al. Sequential cytarabine and α-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res.16, 5303–5311 (2010). ArticleCASPubMedPubMed Central Google Scholar
Pagel, J. M. et al. Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood114, 5444–5453 (2009). Benefits of preconditioning with RIT in elderly patients undergoing bone marrow transplantation for advanced acute myleoid leukaemia and high-risk myelodysplastic syndrome. ArticleCASPubMedPubMed Central Google Scholar
Pagel, J. M. et al. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood113, 4903–4913 (2009). ArticleCASPubMedPubMed Central Google Scholar
Tedder, T. F. & Engel, P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol. Today15, 450–454 (1994). ArticleCASPubMed Google Scholar
Chang, K. L., Arber, D. A. & Weiss, L. M. CD20: a review. Appl. Immunohistochem.4, 1–15 (1996). CAS Google Scholar
Press, O. W. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin. Oncol.30, 10–21 (2003). ArticleCASPubMed Google Scholar
Press, O. W. & Rasey, J. Principles of radioimmunotherapy for hematologists and oncologists. Semin. Oncol.27, 62–73 (2000). A general review of the principles of RIT. CASPubMed Google Scholar
Press, O. W. Physics for practitioners: the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma. Seminars Hematol.37 (Suppl. 7), 2–8 (2000). ArticleCAS Google Scholar
Naruki, Y. et al. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. Int. J. Rad Appl. Instrum. B17, 201–207 (1990). Initial comparison of the differential metabolism of radiometals and radioiodine as radiolabels for RIT. ArticleCASPubMed Google Scholar
Geissler, F., Anderson, S. K. & Press, O. Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. Blood78, 1864–1874 (1991). Article Google Scholar
Geissler, F., Anderson, S. K., Venkatesan, P. & Press, O. Intracellular catabolism of radiolabeled anti-μ antibodies by malignant B-cells. Cancer Res.52, 2907–2915 (1992). CASPubMed Google Scholar
Press, O. W. et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res.56, 2123–2129 (1996). CASPubMed Google Scholar
Kaminski, M. S. et al. Pivotal study of iodine I-131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol.19, 3918–3928 (2001). ArticleCASPubMed Google Scholar
Witzig, T. E. et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol.20, 2453–2463 (2002). ArticleCASPubMed Google Scholar
Press, O. W. et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet346, 336–340 (1995). ArticleCASPubMed Google Scholar
Zalutsky, M. R. Targeted α-particle therapy of microscopic disease: providing a further rationale for clinical investigation. J. Nucl. Med.47, 1238–1240 (2006). Rationale for α-particle therapy illustrated with211At. CASPubMed Google Scholar
Jurcic, J. G. et al. Targeted α particle immunotherapy for myeloid leukemia. Blood100, 1233–1239 (2002). Early work with225Ac. ArticleCASPubMed Google Scholar
Hall, E. J. & Giaccia, A. J. Radiobiology for the Radiologist (Lippincott Williams & Wilkins, 2005). Google Scholar
Mulford, D. A., Scheinberg, D. A. & Jurcic, J. G. The promise of targeted α-particle therapy. J. Nucl Med46 (Suppl. 1), 199S–204S (2005). PubMed Google Scholar
Zalutsky, M. R. & Pozzi, O. R. Radioimmunotherapy with α-particle emitting radionuclides. Q. J. Nucl. Med. Mol. Imaging48, 289–296 (2004). CASPubMed Google Scholar
Couturier, O. et al. Cancer radioimmunotherapy with α-emitting nuclides. Eur. J. Nucl. Med. Mol. Imaging32, 601–614 (2005). ArticleCASPubMed Google Scholar
McDevitt, M. R. et al. Tumor therapy with targeted atomic nanogenerators. Science294, 1537–1540 (2001). The concept of the α-emitter225Ac as anin vivonanogenerator. ArticleCASPubMed Google Scholar
Nilsson, S. et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res.11, 4451–4459 (2005). ArticleCASPubMed Google Scholar
Miederer, M. et al. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J. Nucl. Med.45, 129–137 (2004). CASPubMed Google Scholar
Dahle, J. et al. Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate. Blood110, 2049–2056 (2007). ArticleCASPubMed Google Scholar
Waldmann, T. ABCs of radioisotopes used for radioimmunotherapy: α- and β-emitters. Leuk. Lymphoma44 (Suppl. 3), S107–S113 (2003). ArticleCASPubMed Google Scholar
He, P. et al. Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. Eur. J. Nucl. Med. Mol. Imaging38, 334–342 (2011). ArticlePubMed Google Scholar
Kramer, K. et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J. Clin. Oncol.25, 5465–5470 (2007). Induction of long-term responses in recurrent neuroblastoma with RIT. ArticlePubMed Google Scholar
Kramer, K. et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J. Neurooncol.97, 409–418 (2010). Documentation of an active intrathecal RIT regimen in patients with relapsed CNS neuroblastoma. ArticlePubMed Google Scholar
Carrasquillo, J. A. et al. (124)I-huA33 antibody PET of colorectal cancer. J. Nucl. Med.52, 1173–1180 (2011). Presurgical PET study of antibody targeting of CRC liver metastases as an optimal clinical research design for the study of radioantibody targetingin vivo. ArticlePubMed Google Scholar
O'Donoghue, J. A. et al. 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J. Nucl. Med.52, 1878–1885 (2011). Law of mass action drives antibody–antibody binding at the tumour site. ArticleCASPubMed Google Scholar
Wittrup, K. D., Thurber, G. M., Schmidt, M. M. & Rhoden, J. J. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol.503, 255–268 (2012). The role of diffusion into the tumour, the internalization of antigen and renal clearance in tumour targeting. ArticleCASPubMedPubMed Central Google Scholar
Fujimori, K., Covell, D. G., Fletcher, J. E. & Weinstein, J. N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med.31, 1191–1198 (1990). Initial description of a binding site barrier in RIT. CASPubMed Google Scholar
Pagel, J. M. et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood107, 2184–2191 (2006). ArticleCASPubMedPubMed Central Google Scholar
Winter, J. N. et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol.27, 1653–1659 (2009). ArticleCASPubMedPubMed Central Google Scholar
Devizzi, L. et al. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J. Clin. Oncol.26, 5175–5182 (2008). ArticleCASPubMed Google Scholar
Nademanee, A. et al. A Phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood106, 2896–2902 (2005). ArticleCASPubMedPubMed Central Google Scholar
Kaminski, M. S. et al. Radioimmunotherapy of B-cell lymphoma with 131I anti-B1 (anti-CD20) antibody. N. Engl. J. Med.329, 459–465 (1993). Development of a practical regimen for outpatient therapy of lymphoma with RIT. ArticleCASPubMed Google Scholar
Horning, S. J. et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol.23, 712–719 (2005). ArticleCASPubMed Google Scholar
Goldenberg, D. M., Morschhauser, F. & Wegener, W. A. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk. Lymphoma51, 747–755 (2010). ArticleCASPubMed Google Scholar
Davis, T. A. et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin. Cancer Res.10, 7792–7798 (2004). Documentation of the role of radionuclides in anti-CD20 RIT. ArticleCASPubMed Google Scholar
Fisher, R. I. et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J. Clin. Oncol.23, 7565–7573 (2005). ArticleCASPubMed Google Scholar
Bennett, J. M. et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine 131I tositumomab. Blood105, 4576–4582 (2005). ArticleCASPubMed Google Scholar
Mones, J. V. et al. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. Leuk. Lymphoma48, 342–348 (2007). ArticleCASPubMed Google Scholar
Czuczman, M. S. et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J. Clin. Oncol.25, 4285–4292 (2007). ArticleCASPubMed Google Scholar
Sharkey, R. M., Press, O. W. & Goldenberg, D. M. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood113, 3891–3895 (2009). ArticleCASPubMedPubMed Central Google Scholar
Johnson, T. A. & Press, O. W. Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int. J. Cancer85, 104–112 (2000). ArticleCASPubMed Google Scholar
Gopal, A. K. et al. Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age >/= 60 years with B cell lymphoma. Biol. Blood Marrow Transplant20, 770–775 (2014). ArticleCASPubMedPubMed Central Google Scholar
Press, O. W. et al. A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood96, 2934–2942 (2000). ArticleCASPubMed Google Scholar
Witzig, T. E. et al. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a Phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica99, 1738–1745 (2014). ArticleCASPubMedPubMed Central Google Scholar
Press, O. W. et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J. Clin. Oncol.24, 4143–4149 (2006). ArticleCASPubMed Google Scholar
Leonard, J. P. et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J. Clin. Oncol.23, 5696–5704 (2005). ArticleCASPubMed Google Scholar
Jacobs, S. A. et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin. Cancer Res.14, 7088–7094 (2008). ArticleCASPubMed Google Scholar
Zinzani, P. L. et al. A Phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann. Oncol.19, 769–773 (2008). ArticleCASPubMed Google Scholar
Zinzani, P. L. et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a Phase II non-randomised trial (FLUMIZ). Lancet Oncol.9, 352–358 (2008). ArticleCASPubMed Google Scholar
Zinzani, P. L. et al. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin. Cancer Res.16, 3998–4004 (2010). ArticleCASPubMed Google Scholar
Zinzani, P. L. et al. A Phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer112, 856–862 (2008). ArticleCASPubMed Google Scholar
Link, B. K. et al. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter Phase II study. J. Clin. Oncol.28, 3035–3041 (2010). ArticleCASPubMed Google Scholar
Morschhauser, F. et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol.26, 5156–5164 (2008). ArticleCASPubMed Google Scholar
Press, O. W. et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J. Clin. Oncol.31, 314–320 (2013). ArticleCASPubMed Google Scholar
Husband, J. E. et al. Evaluation of the response to treatment of solid tumours — a consensus statement of the International Cancer Imaging Society. Br. J. Cancer90, 2256–2260 (2004). ArticleCASPubMedPubMed Central Google Scholar
Schaefer, N. G., Ma, J., Huang, P., Buchanan, J. & Wahl, R. L. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U. S. medical oncologists and hematologists. J. Nucl. Med.51, 987–994 (2010). ArticlePubMed Google Scholar
Matthews, D. C. et al. Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood94, 1237–1247 (1999). ArticleCASPubMed Google Scholar
McDevitt, M. R., Finn, R. D., Ma, D., Larson, S. M. & Scheinberg, D. A. Preparation of α-emitting 213Bi-labeled antibody constructs for clinical use. J. Nucl. Med.40, 1722–1727 (1999). CASPubMed Google Scholar
Rosen, S. T. et al. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J. Clin. Oncol.5, 562–573 (1987). ArticleCASPubMed Google Scholar
Zhang, M. et al. The anti-CD25 monoclonal antibody 7G7/B6, armed with the α-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res.66, 8227–8232 (2006). ArticleCASPubMed Google Scholar
Gopal, A. K., Pagel, J. M., Fromm, J. R., Wilbur, S. & Press, O. W. 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. Blood113, 5905–5910 (2009). ArticleCASPubMedPubMed Central Google Scholar
Dietlein, M. et al. Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma. Studies with cell lines and animal studies. Nuklearmedizin49, 97–105 (2010). ArticleCASPubMed Google Scholar
Ocean, A. J. et al. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a Phase 1 trial. Cancer118, 5497–5506 (2012). ArticleCASPubMed Google Scholar
Reardon, D. A. et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J. Clin. Oncol.24, 115–122 (2006). ArticleCASPubMed Google Scholar
Reardon, D. A. et al. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol.10, 182–189 (2008). ArticleCASPubMedPubMed Central Google Scholar
Zalutsky, M. R. et al. Clinical experience with α-particle-emitting At-211: treatment of recurrent brain tumor patients with At-211-labeled chimeric antitenascin monoclonal antibody 81C6. J. Nuclear Med.49, 30–38 (2008). ArticleCAS Google Scholar
Xu, H., Cheung, I. Y., Guo, H. F. & Cheung, N. K. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res.69, 6275–6281 (2009). ArticleCASPubMedPubMed Central Google Scholar
Spector, R. & Mock, D. M. Biotin transport and metabolism in the central nervous system. Neurochem. Res.13, 213–219 (1988). ArticleCASPubMed Google Scholar
Davson, H. & Segal, M. B. in Physiology of the CSF and Blood–Brain Barriers 489–523 (CRC Press, 1996). Google Scholar
Goodwin, D. A., Meares, C. F. & Osen, M. Biological properties of biotin–chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system. J. Nucl. Med.39, 1813–1818 (1998). Initial biotin–avidin for multistep targeting. CASPubMed Google Scholar
Rosebrough, S. F. Pharmacokinetics and biodistribution of radiolabeled avidin, streptavidin and biotin. Nucl. Med. Biol.20, 663–668 (1993). ArticleCASPubMed Google Scholar
Paganelli, G. et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res.51, 5960–5966 (1991). CASPubMed Google Scholar
Humm, J. L., Chin, L. M. & Macklis, R. M. F(ab')2 fragments versus intact antibody — an isodose comparison. J. Nucl. Med.31, 1045–1047 (1990). CASPubMed Google Scholar
Sharkey, R. M. & Goldenberg, D. M. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest.24, 82–97 (2006). ArticlePubMed Google Scholar
Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J. & Chatal, J. F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol.24, 823–834 (2006). Novel forms of pre-targeting in RIT. ArticleCASPubMed Google Scholar
Kenanova, V. et al. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv–Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res.67, 718–726 (2007). ArticleCASPubMed Google Scholar
Larson, S. M. et al. Single chain antigen binding protein (sFv CC49): first human studies in colorectal carcinoma metastatic to liver. Cancer80, 2458–2468 (1997). ArticleCASPubMed Google Scholar
Waldmann, T. A. et al. Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood86, 4063–4075 (1995). ArticleCASPubMed Google Scholar
Hnatowich, D. J., Virzi, F. & Rusckowski, M. Investigations of avidin and biotin for imaging applications. J. Nucl. Med.28, 1294–1302 (1987). CASPubMed Google Scholar
Axworthy, D. B. et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl Acad. Sci. USA97, 1802–1807 (2000). Optimized regimen for streptavidin–biotin multistep targeting of solid tumours, with excellent targetingin vivowith tumour-to-blood therapeutic index of approximately 70, for a reagent that was ultimately introduced into humans. ArticleCASPubMedPubMed Central Google Scholar
Schultz, J. et al. A tetravalent single-chain antibody–streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res.60, 6663–6669 (2000). CASPubMed Google Scholar
Paganelli, G. et al. Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int. J. Cancer45, 1184–1189 (1990). ArticleCASPubMed Google Scholar
Goodwin, D. A. & Meares, C. F. Advances in pretargeting biotechnology. Biotechnol. Adv.19, 435–450 (2001). ArticleCASPubMed Google Scholar
Zhang, M. et al. Pretarget radiotherapy with an anti-CD25 antibody–streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc. Natl Acad. Sci. USA100, 1891–1895 (2003). ArticleCASPubMedPubMed Central Google Scholar
Press, O. W. et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood98, 2535–2543 (2001). ArticleCASPubMed Google Scholar
Pagel, J. M. et al. Comparison of a tetravalent single-chain antibody–streptavidin fusion protein and an antibody–streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. Blood108, 328–336 (2006). ArticleCASPubMedPubMed Central Google Scholar
Sharkey, R. M. et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res.63, 354–363 (2003). CASPubMed Google Scholar
Barbet, J. et al. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother. Radiopharm.14, 153–166 (1999). ArticleCASPubMed Google Scholar
Gautherot, E. et al. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J. Nucl. Med.41, 480–487 (2000). CASPubMed Google Scholar
Chang, C. H., Rossi, E. A. & Goldenberg, D. M. The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin. Cancer Res.13, 5586s–5591s (2007). ArticleCASPubMed Google Scholar
Rossi, E. A. et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc. Natl Acad. Sci. USA103, 6841–6846 (2006). ArticleCASPubMedPubMed Central Google Scholar
Chmura, A. J., Orton, M. S. & Meares, C. F. Antibodies with infinite affinity. Proc. Natl Acad. Sci. USA98, 8480–8484 (2001). Multistep targeting with antibodies that bind covalently to the tumour. ArticleCASPubMedPubMed Central Google Scholar
Butlin, N. G. & Meares, C. F. Antibodies with infinite affinity: origins and applications. Acc. Chem. Res.39, 780–787 (2006). ArticleCASPubMed Google Scholar
Orcutt, K. D. et al. A modular IgG-scFv bispecific antibody topology. Protein Eng. Des. Sel.23, 221–228 (2010). Initial design for a DOTA-based PRIT. ArticleCASPubMed Google Scholar
Chen, X. et al. Synthesis and in vitro characterization of a dendrimer–MORF conjugate for amplification pretargeting. Bioconjug Chem.19, 1518–1525 (2008). ArticleCASPubMedPubMed Central Google Scholar
Liu, X., Wang, Y., Nakamura, K., Kubo, A. & Hnatowich, D. J. Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery. Cancer Gene Ther.15, 126–132 (2008). ArticleCASPubMed Google Scholar
Cheal, S. M. et al. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG–scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol. Cancer Ther.13, 1803–1812 (2014). ArticleCASPubMedPubMed Central Google Scholar
Forero, A. et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood104, 227–236 (2004). Initial human trials in lymphoma with multistep targeting based on streptavidin–biotin binding. ArticleCASPubMed Google Scholar
Forero-Torres, A. et al. Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother. Radiopharm.20, 379–390 (2005). ArticleCASPubMed Google Scholar
Knox, S. J. et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res.6, 406–414 (2000). CASPubMed Google Scholar
Kraeber-Bodere, F. et al. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin. Cancer Res.9, 3973S–3981S (2003). CASPubMed Google Scholar
Aarts, F. et al. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody. Cancer116, 1111–1117 (2010). ArticleCASPubMed Google Scholar
Vuillez, J. P. et al. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a Phase I/II trial. Clin. Cancer Res.5, 3259s–3267s (1999). CASPubMed Google Scholar
Kraeber-Bodere, F. et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a Phase I/II clinical trial. Clin. Cancer Res.5, 3190s–3198s (1999). CASPubMed Google Scholar
Grana, C. et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer86, 207–212 (2002). ArticleCASPubMedPubMed Central Google Scholar
Walter, R. B., Press, O. W. & Pagel, J. M. Pretargeted radioimmunotherapy for hematologic and other malignancies. Cancer Biother. Radiopharm.25, 125–142 (2010). General review of the potential and pitfalls of PRIT. ArticleCASPubMedPubMed Central Google Scholar
Emami, B. et al. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys.21, 109–122 (1991). ArticleCASPubMed Google Scholar
Maxon, H. R. et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N. Engl. J. Med.309, 937–941 (1983). ArticleCASPubMed Google Scholar
Larson, S. M. et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J. Nucl. Med.33, 2020–2023 (1992). Initial use of PET scanning for dosimetry in humans: initial theranostic applications. CASPubMed Google Scholar
Kramer, K. et al. Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates. J. Neurooncol35, 101–111 (1997). ArticleCASPubMed Google Scholar
Cheung, N. K. et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte–macrophage colony-stimulating factor and 13-_cis_-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J. Clin. Oncol.30, 3264–3270 (2012). ArticleCASPubMedPubMed Central Google Scholar
Cheung, N. K. et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J. Nucl. Med.45, 867–877 (2004). CASPubMed Google Scholar
Hainsworth, J. D. et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin. Lymphoma Myeloma9, 223–228 (2009). ArticleCASPubMed Google Scholar
Zinzani, P. L. et al. A Phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. Ann. Oncol.23, 415–420 (2012). ArticleCASPubMed Google Scholar
Morschhauser, F. et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J. Clin. Oncol.31, 1977–1983 (2013). ArticleCASPubMed Google Scholar
Scheinberg, D. A. et al. A Phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J. Clin. Oncol.9, 478–490 (1991). ArticleCASPubMed Google Scholar
Allen, B. J. et al. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy3, 1041–1050 (2011). ArticleCASPubMed Google Scholar
Allen, B. J. et al. Intralesional targeted α therapy for metastatic melanoma. Cancer Biol. Ther.4, 1318–1324 (2005). ArticleCASPubMed Google Scholar
Raja, C. et al. Interim analysis of oxicity and response in Phase 1 trial of systemic targeted α therapy for metastatic melanoma. Cancer Biol. Ther.6, 846–852 (2007). ArticleCASPubMed Google Scholar